NCT04162834 is a Phase 4 clinical trial of Papaverine in Kidney Cancer, sponsored by Asan Medical Center.

Who is sponsoring NCT04162834?

NCT04162834 is sponsored by Asan Medical Center.

What drugs are being tested in NCT04162834?

Interventions in NCT04162834: Papaverine, Normal saline.

What condition does NCT04162834 study?

NCT04162834 studies Kidney Cancer.

Is NCT04162834 still recruiting?

NCT04162834 is currently completed. Last updated 19 April 2021.

Last reviewed 2021-04-19 · How we verify

NCT04162834

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Papaverine on Renal Artery Blood Flow Volume

Completed Phase 4 Last updated 19 April 2021

What this trial tests

Phase 4 trial testing Papaverine in Kidney Cancer in 96 participants. Completed in 15 April 2021.

Timeline

21 November 2019

Primary endpoint
15 April 2021

15 April 2021

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	96
Start date	21 November 2019
Primary completion	15 April 2021
Estimated completion	15 April 2021
Sites	1 location across South Korea

Drugs / interventions tested

Papaverine — full drug profile →
Normal saline

Conditions studied

Kidney Cancer — all drugs for Kidney Cancer →

Sponsor

Asan Medical Center

Who can join

Adults 20 to 79, any sex, with Kidney Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effect of papaverine on renal artery blood flow after declamping of renal artery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Papaverine

Trials testing the same drug.

NCT06834126 — Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial · Phase 1 · recruiting
NCT06550232 — IV PAPAVERINE Prior to Propess for Labor Induction · Phase 4 · completed
NCT05136846 — Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer · Phase 1 · recruiting
NCT03894904 — Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients · Phase 4 · completed

Other recruiting trials for Kidney Cancer

Currently open trials in the same condition.

NCT07401875 — A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) · Phase 1 · recruiting
NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
NCT06964958 — 177LuPSMA in Renal Cell Carcinoma · Phase 2 · active not recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04162834 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 19 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04162834.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing